18:35 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million June 18 through two convertible note rounds led by Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis Investment Management,...
22:08 , Jun 18, 2018 |  BC Extra  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million Monday through two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis Investment Management, BVCF Management, CMBC Capital Holdings,...
00:21 , Mar 22, 2018 |  BC Innovations  |  Translation in Brief

Mining marine metabolites

Bristol-Myers Squibb Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for immuno-oncology. Atlantis applies data mining, computational modeling and machine learning technology to screen microbiome-derived metabolites against cellular and biochemical...
23:20 , Mar 1, 2018 |  BC Innovations  |  Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
20:01 , Feb 16, 2018 |  BC Week In Review  |  Company News

Sirenas, BMS partner on drug discovery for "challenging" targets

Sirenas LLC (San Diego, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug discovery platform against several undisclosed "challenging" targets. ATLANTIS uses machine learning to discover microbiome-derived metabolites, which then form the...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

California Institute for Biomedical Research, Sirenas LLC deal

Sirenas and the institute partnered to discover and develop small molecules in oncology, neurology, regenerative medicine and neglected diseases. Sirenas will provide the institute access to the company’s marine-derived chemical diversity and Atlantis data mining...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Lurbinectedin: Phase III started

PharmaMar began the open-label, international Phase III ATLANTIS trial to compare PM1183 plus doxorubicin vs. topotecan or cyclophosphamide plus doxorubicin and vincristine in 600 patients with SCLC who have failed 1 prior platinum-containing regimen. PharmaMar...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Atlantis S.A. de C.V. deal

Valeant will acquire assets from branded generic company Atlantis, including gastrointestinal, analgesics and anti-inflammatory products for about $71 million. According to Valeant, the acquired assets generated 2011 revenue of $26 million and are expected to...
08:00 , Mar 17, 2003 |  BC Week In Review  |  Company News

Atlantis BioActives Corp., Bioxel deal

Atlantis will provide large-scale production of intermediate taxanes extracted from BIP’s yew biomass for cGMP paclitaxel production. Atlantis BioActives Corp. , Charlottetown, Prince Edward Island   Bioxel Pharma Inc. (TSE:BIP), Montreal, Quebec   Business: Supply/Service...
07:00 , Jul 27, 1998 |  BC Week In Review  |  Clinical News

Activase alteplase tPA: Phase III data; marketed

GNE terminated its U.S. Phase III ATLANTIS trial (Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke) after an independent Data Safety Monitoring Board concluded from an interim analysis that the trial had an extremely...